Issue 16 2012
www.pharmafocusasia.com
Key Elements of the FDA’s Draft Biosimilars Guidance First Compulsory License Likely to impact the pharmaceutical industry in India Good Clinical PracticeCompliant Clinical Studies in China
In Association with